Insights Success is The Best Business Magazine in the world for enterprises. Being a platform, to growing pharmaceutical companies in 2017

1. The way of business solutionsThe way of business solutions
October 2017October 2017
www.insightssuccess.inwww.insightssuccess.in
ENYO PharmaLeveraging viruses to develop first-in-class drug candidates
in many indications
Fastest Growing
Companies 2017
The
1
Pharmaceutical
Dr. Jacky Vonderscher
Co-founder & CEO
PhotoCourtesy:FlorentDubray
Revolutionary Factors
Affecting Pharmaceutical Industry
Market Dashboard
Social Media Marketing
for Pharma Industry
Editor’s Pick

4. Editorial
harma Industry has sustained decades of modest growth along
Pwith a healthy list of historical medical achievements.
Technological developments in the pharmaceutical industry-
from potent new drug chemistries to innovative R&D partnerships and
marketing plans are reshaping the industry strategies of many
pharmaceutical and biotechnology companies. According to the
recently published report, the last five years of Thomson Reuters Top
100 Global Innovators list consistently release pharma as one of the
largest industry sectors represented. Though innovation is the lifeblood
of any industry, the discovery and development of new drugs are
supplemented by a host of unique challenges, ethical implications, and
social responsibilities. The fundamental role of the pharmaceutical
industry in maintaining and enhancing human life is further exhibited in
the extent of its R&D activity. By some accounts, pharmaceutical R&D
holds an impressive share of all business spending on R&D worldwide-
a remarkable financial commitment to a single industry.
Ranking pharma innovation isn’t easy. One typically includes new
drugs approved, but that only gauges quantity, not quality. Several
attempts at assessing quality have been made using such criteria as new
modes of action; therapeutic need; medical value; or improvement over
the standard of care. While some of these provide useful self-supporting
insights, the acid-test of innovation ultimately is the impact it has on
public health. Thomas Reuters proposed new quantitative measures of
productivity and innovation and used these to represent an industry that
has become more innovative and productive. These innovative
measures include two quantitative standards of the industry based on
the parameters collected for measuring productivity and innovation.
Assessing the current state the industry by these new standards will
allow a more qualitative view of the state of the pharmaceutical
industry and can be used to measure improvements in both productivity
and innovation. Companies with an innovation edge will have a
substantial competitive advantage.
Quality Measures
Driving Innovation
in Pharma Industry
Sugandha Sharma

5. ,7
Insights Success Media Tech LLC
555 Metro Place North, Suite 100,
Dublin, OH 43017, United States
Phone - (614)-602-1754
Email: info@insightssuccess.com
For Subscription: Visit www.insightssuccess.com
Insights Success Media and Technology Pvt. Ltd.
Ofce No. 510, 513, 5th Floor, Rainbow Plaza,
Shivar Chowk, Pimple Saudagar, Pune, Maharashtra 411017
Phone - India: 020-69400110, 111, 112
Email: info@insightssuccess.in
For Subscription: Visit www.insightssuccess.in
sales@insightssuccess.com
Corporate Ofces:
October 2017
Database Management Steve
Technology Consultant Swapnil Patil
Circulation Manager Robert
Research Analyst Jennifer
David, Joseph,
John, Mary
Editor-in-Chief Pooja M. Bansal
Ariana LawrenceSenior Editor
Managing Editor Sugandha Sharma
Art & Design Director Victoria
Co-designer Alex Noel
Visualiser David King
Business Development Manager Mathew Smith
Business Development Executive
Pranita ManePicture Editor
Marketing Manager Chris
Nick Adams
Art Editor Vijaykumar Dudhbhate
Contributor
Nikita Doiphode

6. Articles
08
ENYO Pharma:
Leveraging viruses to
develop first-in-class
drug candidates in
many indications
CoverStory
An Imperative
Association between
Neuroscience and
e-Learning
22
Exclusive
Revolutionary
Factors Affecting
Pharmaceutical
Industry
42
Editor’s Pick
Artificial Intelligence:
A Game Changer
for Healthcare
34
Innovation Archives
Social Media
Marketing for
Pharma Industry
28
Market Dashboard

7. ICM Pharma:
Transforming Science
of Drug Development20 32
Quertle:
Transforming AI-Based
Analytics for Biomedical
Big Data
Contents
16
How Innovation in healthcare
means going against entrenched
beliefs about the nature of
charting
Expert’s Column
26
Top 5 Best Practices
that Defines a
Successful Wellness
Program
Executive Talk
38
Hospital Logistics:
Accelerating the Patient
Flow in Danish Hospitals
Professional’s Particulars

8. Recent years have seen exciting breakthroughs in pharmaceutical sciences that are producing genuinely
novel therapeutics for unmet patient needs. The challenging market dynamics have transformed the
conventional pharmaceutical industry model from one of developing low-cost drugs of incremental
advantage for large patient populations to one of efficient, high-value medicines for targeted, niche patient
populations.
The most prosperous firms are shifting away from a traditional, top-down model of product promotion and
toward a flexible, interactive approach: “Patients First,” which gives patients better tools and full focused
information on the drugs they are taking and how to control their conditions. Pharma companies that succeed in
patient engagement efforts increase their chances of regulative and commercial success as judgments about
approval, prescribing, and marketing of drugs are more closely tied to patient results and needs. From a business
perspective, this changes everything as pharma companies will need to become more proactive with large
patients communities.
The need for proficient pharmaceutical solution providers has made us look out for “The 10 Fastest Growing
Pharmaceutical Companies 2017.” On the cover page, we have Dr. Jacky Vonderscher, the Co-founder &
CEO of ENYO Pharma, that bringing new opportunities to the Pharmaceutical Industry. ENYO Pharma is a
biopharmaceutical company with an innovative approach inspired by viruses, and that leveraging viruses to
develop first-in-class drug candidates in multiple indications. Their biotech mimics virus strategy is to modulate
host cellular functions with numerous applications. Initially, ENYO Pharma developed against influenza virus; it
has a mitochondrial cellular target which leads ENYO Pharma to explore new indications such as oncology or
metabolic diseases.
To add an interesting angle in this edition, we have come up with some knowledge enriching articles from the
experts of the industry like “Top 5 Best Practices that Defines a Successful Wellness Program” by Dr. Gary Tho,
owner at Chiropractic Works, and “How Innovation in healthcare means going against entrenched beliefs about
®
the nature of charting” by Richard Low, MD of Praxis Electronic Medical Records. Along with such amazing
pieces to read about pharma and healthcare, we have also covered some of the amazing articles crafted by
editorial desk like Social Media Marketing for Pharma Industry, An Imperative Association between
Neuroscience and e-Learning, Artificial Intelligence: A Game Changer for Healthcare, and Revolutionary
Factors Affecting Pharmaceutical Industry, among many others.
Do flip every single page to unveil the secret of the success of these companies. Hope this issue will leave a
mark on your mind and will enrich your knowledge about Pharmaceutical.
Post-Genetic Era requires “Patient-First”
approach from Pharma Industries

9. 1800 102 2055
TELLING
LIFE’S
STORIES
FROM
MEMORY

10. ENYO
Pharma
‘‘
Leveraging viruses to develop rst-in-class
drug candidates in many indications
ENYO Pharma has licensed several Inserm patents
issued from the discoveries of the founding scientists
and developed a unique approach for the identification
of intracellular therapeutic targets and first-in-class
molecules
‘‘

11. Cover Story
PhotoCourtesy:FlorentDubray
Dr. Jacky Vonderscher
Co-founder & CEO

12. In the last decade, the pharmaceutical sector has been facing structural issues when it comes to bringing new
pharmaceuticals to the patient. Indeed, studies have revealed that the average cost to develop a single drug
has tripled to greater than €1.7Bn in real terms since 2003 while numerous patent expirations have reduced
revenues from blockbuster drugs. Also, the average forecast for peak sales has declined by 43% due to increasing
development of specialized drugs for smaller patient populations.
Lastly, the attrition in the drug development pipeline remains high notably for lack of efficacy. On average, 24
failed drug development programs occur for every one molecule entering to market.
In a word, the process of developing a new drug is very time consuming, extremely costly and highly risky, with
minimum chance of a successful outcome.
In addition, the rate of innovation in pharmaceutical development is low, which results from a focus on a
restricted number of drug target classes considered more tractable. One answer to that was to develop “me-too”
drugs, which are clinically equivalent therapeutics to replace pioneering drugs as opposed to focusing on new
targets.
Still there are a large number of diseases with unmet medical needs because of a lack of innovation and new
cellular targets investigated by the pharmaceutical industry. In the last decade there has been growing awareness
of the limited structural diversity in pharmaceutical company compound collections but there are still room for
new approaches and new therapeutic strategies.
The Pharmaceutical Industry: A Sector Facing Issues In Innovation
“We have plans to conduct all our
molecules to Phase II Proof of Concept
clinical trials”
PhotoCourtesy:ENYOPharma

13. Having made that
analysis, two veterans
of the pharma industry
and four scientists of
the Infectiology
Research Center in
Lyon, France created
ENYO Pharma in
January 2014.
ENYO Pharma is on
the mission to create a
change by developing
new therapies against
diseases with unmet
medical needs thanks to
a wholly new approach.
ENYO Pharma’s team
has developed a unique
and innovative drug
discovery engine
inspired by viruses to
identify and develop
first-in-class drug candidates in multiple attractive diseases.
The company is currently developing its first leading product EYP001 in two liver diseases: chronic hepatitis B
and NASH (Non-alcoholic steatohepatitis). However many other therapeutic areas such as oncology or metabolic
disorders are also being investigated through ongoing development programs.
Dr. Jacky Vonderscher, the Erudite behind ENYO Pharma
ENYO Pharma: Bringing New Opportunities to the Pharmaceutical Industry
ENYO Pharma’s team is world class with a crucial mix of pharma senior leadership and scientific excellence
notably in virology which drives the company forward. But a team can only coordinate thoughtfully and march
forward towards excellence when they get a good leader. And ENYO has a genius as its leader, the co-founder
and Chief Executive Officer of the company, Dr. Jacky Vonderscher, a pharma veteran and an experienced
drug hunter. He saw the potential to rapidly translate the expertise in virus-host interactions of ENYO Pharma’s
scientists into novel drug candidates in many attractive conditions beyond infectious diseases.
Dr. Vonderscher held multiple Senior Executive roles notably in R&D. Previously he was operating as a Senior
VP Head of Translation Research Sciences and as a Senior VP Head of Molecular Medicine Labs at Roche in
USA and Switzerland (2008-2012). He also held other senior positions with Novartis in the USA and Switzerland
®
(1979 to 2008). He is well known for his leading role in the discovery and development of Sandimmum Neoral
in the 90s and was also involved as co-inventor of two other important drug products, the blockbuster Everolimus
® ®
(Certican and Afinitor Products) and Mycophenolic Acid Sodium salt (Myfortic® Product) He’s a Board
member of Inatherys, ObsEva and Step Pharma as well as a SAB member of Inotrem. He recently was also
coopted as a board member of EBE (European Biopharmaceutical Entreprises, a European Trade Association).
PhotoCourtesy:ENYOPharma

14. Over millions of years of evolution, viruses have perfected their ability to
modulate and hijack the cell functions for their own benefit.
ENYO Pharma's team is convinced that by imitating viruses it is possible to
modulate cellular functions and proteins without endangering the cell to
open new perspectives for developing medicines.
ENYO Pharma’s team is thus developing drug discovery programs on many
intracellular host targets yet untapped by pharmaceutical industries because
considered as non-tractable until now. This would lead to the development
of first in class therapeutics.
The approach allows finding new cellular targets which are not exploited yet
to diversify the current therapeutic pipeline and increase the chance of
getting a cure for diseases with still unmet medical needs.
This approach matches the needs of the large Pharma to replenish their
pipelines with innovative drugs through in licensing, maintains the primacy
of public health interest and maximizes individual medical benefit.
ENYO Pharma’s expertise and knowledge have also raised the interest of major investors, who invested €22M in
the company in early 2016 to continue the work on Hepatitis B and other programs. The company is currently
discussing with various US and European investors to raise its Series B to fund its two Phase II in chronic
hepatitis B and NASH and bring at least one new compound in clinic.
ENYO Pharma already made the proof-of-concept of its drug discovery engine with its first candidate EYP001
being tested in patients. It second leading molecule, EYP002 was inspired by a strategy employed by Influenza to
regulate host cell biology and allowed to find a unique novel target focused on mitochondria and stress responses
that could also be relevant
for oncology and metabolic diseases.
Following that, ENYO has received funding from the European Union’s Horizon 2020 research and innovation
program for the MIMESIS project that results from the scale up of ENYO Pharma’s innovative drug discovery
engine and aims at screening 10,000 molecules. This library of developable chemical templates is currently
screened in phenotypic assays against 4 viruses (Flu, RSV and HRV (to respiratory viruses) and Zika), a
mycobacterium (TB) and as inducers of Immunogenic Cell Death in tumors. With €3.6 million spending over 24
months, most promising chemistries will be the starting point for numerous hit to lead optimization programs
funded within the EU grant.
The initial results showed a high number of leads and as a single organization ENYO Pharma will not be able to
develop them all and will likely partnerships to licence or co-develop some of those molecules that are not part of
an internal specific program.
Drug Discovery Inspired by Viruses
Other programs (EYP002, MIMESIS): ENYO Pharma further
validation of ENYO’s approach
Photo Courtesy: ENYO Pharma

15. PhotoCourtesy:ENYOPharmaENYO Pharma is developing its leading drug candidate in both chronic Hepatitis B and NASH.
NASH is the most common liver disorder in Western countries. Its main consequence is liver fibrosis, cirrhosis
and hepatocellular carcinoma. Currently no treatment exists for this disease which represents an important
challenge.
Hepatitis B remains a major worldwide public health problem with over 260 millions of chronically-infected
people despite extensive vaccination programs. Chronic hepatitis B evolves towards life threatening complications
including liver cirrhosis and cancer. Current therapeutic regimen, often fail to cure HBV and are lifelong
treatments.
Recently, ENYO Pharma has successfully completed EYP001 first in man Phase 1 study. The Phase 1a single and
multiple ascending dose trial evaluating EYP001 in healthy subjects have been completed. The results show that
EYP001 was safe and well-tolerated at all doses studied in 80 subjects. The drug is now starting a phase 1b
clinical trial in patients with chronic HBV with results due in early 2018 with two phase 2 trials in HBV and
NASH planned for mid 2018.
“Thanks to the MIMESIS approach, ENYO Pharma will multiply the opportunities to bring very innovative drugs
working on untapped human targets which will translate into higher pharmaceutical benefit to patients. This
approach has not been used before in the pharmaceutical industry and is potentially transferable to any human
disease. Within less than a year we have already gained 50 hit molecules on undrugged targets and they are being
validated as we speak” asserts Dr. Vonderscher.
“We have deciphered virus-host interactions and built a unique
Drug Discovery Engine based on mimetism of the virus strategy
for modulation of cellular host functions”
Feather of Achievement in ENYO Pharma’s Cap

16. Address :
Country :City : State : Zip :
Date :
Check should be drawn in favor of : INSIGHTS SUCCESS MEDIA TECH LLC
Name :
Telephone :
Email :
1 Year.......... $250.00(12 Issues) .... 6 Months ..... (06 Issues) ..... $130.00
3 Months ... (03 Issues) .... $70.00 1 Month ...... (01 Issue) ..... $25.00
Yes I would like to subscribe to Insights Success Magazine.
Global Subscription
Never Miss an Issue
Insights Success Media Tech LLC
555 Metro Place North, Suite 100,
Dublin, OH 43017, United States
Phone - (614)-602-1754,(302)-319-9947
Email: info@insightssuccess.com
For Subscription : www.insightssuccess.com
CORPORATE OFFICE

17. Management BriefCompany Name
ENYO Pharma
enyopharma.com
Dr. Jacky Vonderscher
Co-founder & CEO
ENYO Pharma is a privately held biopharmaceutical company
with an innovative approach inspired by viruses; their biotech
mimics virus strategy to modulate host cellular functions with
multiple applications.
Dr. Farhad Parhami
Founder & President
Leo Pharma
leo-pharma.com
LEO Pharma helps people to achieve healthy skin by offering
care solutions to patients in more than 100 countries globally,
supports people in managing their skin conditions.
MAX BioPharma
maxbiopharma.com
MAX BioPharma is a California-based biotechnology firm
developing novel small molecule lipids, referred to as oxysterols,
as candidates for therapeutic drugs for debilitating and fatal
human diseases.
Senhwa Biosciences
Inc.
senhwabiosciences.com
Saniona is a research and development company focused on drugs
for central nervous system disorders, autoimmune diseases,
metabolic diseases and pain relief; has a comprehensive portfolio of
potential drug candidates in preclinical or clinical phase.
Quertle, LLC
quertle.com
Dr. Rajesh C. Shrotriya
MD, Chairman & CEO
Spectrum Pharmaceuticals is an American biopharmaceutical
company, located in Irvine, California; is a commercial-stage
biotechnology company with fully integrated commercial and drug
development operations, and a leader in hematology and oncology.
Senhwa Biosciences (Senhwa) is a drug development company,
engaged in development of small molecule drugs for treating newly
validated targets in cancer pathways; pipeline product portfolio
includes two agents in clinical development for cancer, namely,
CX-5461 and CX-4945.
Spectrum Pharmaceuticals
Inc.
sppirx.com
Dr. Tai-Sen T. Soong
President & CEO
ARCA Biopharma, Inc.
arcabio.com
ARCA was founded on the belief that a precision medicine approach
to drug development, tailoring medical treatment to the individual
genetic characteristics of patients, can enable more effective
therapies, improve patient outcomes and reduce healthcare costs.
About Capella
Therapeutics, Inc.
capellatherapeutics.com
Capella Therapeutics is founded in 2014 in San Diego, focused
on the discovery and development of small molecule drugs to
treat cancer and inflammatory diseases.
ICM Pharma Pte. Ltd.
icmpharma.com
Dr. Stuart Koe
Managing Director
ICM Pharma is a Singapore-based, GMP-certified
pharmaceutical manufacturer that develops, manufactures and
markets a range of OTC and generic pharmaceuticals.
Saniona
saniona.com
Dr. Jeffrey Saffer &
Dr. Vicki Burnett
Founders
Dr. Yun Long
Founder & CEO
Quertle is a Biomedical Big Data leader; their BioAI™ Platform
- based on advanced Artificial Intelligence - powers a suite of
products that deliver relevant information and predictive
analytics out of the flood of biomedical textual information.
Dr. Jørgen Drejer
Founder & CEO
Derek Cole
VP
Henrik Heskjær Kyndlev
Head of Global External
Communication

18. merican Medicine is in an
Aunprecedented crisis. Doctors
are not happy. A recent study
by the AMA shows that physicians are
spending twice as much time with their
Electronic Healthcare Records (EHRs)
as they are in “direct clinical face-
time” with their patients. The study
also revealed widespread career
dissatisfaction among physicians with
54% reporting “physician burnout.”
Doctors are wasting hours a day
struggling with their computers to
document medicine and provide care to
patients with whom they spend less
time every day. Patients feel their
doctor is more concerned with data on
the computer than listening to their
problems and caring for their needs.
Meanwhile health care costs are
climbing while providers are getting
progressively more frustrated at
playing data entry clerks.
Remarkably, computers were first
introduced to the examination room
precisely to resolve the chaos that
clinicians faced with paper. Initially,
computers promised to make
documentation easier and more
effective. Instead, EHRs severely
worsened an admittedly a bad
situation. What is even stranger is that
in all other fields of endeavor except
medicine, information technology has
been highly successful in streamlining
paperwork and bureaucratic
congestion. Why has this not happened
in healthcare?
One strange explanation propounded
many in the IT field is that doctors are
“computer-phobic,” that physicians
fear technology and lack the adequate
technical skills to handle computers.
Nothing could be further from the
truth. Physicians are highly-trained in
the sciences and have used every new
technology appearing in the medical
field effectively for at least a hundred
years. Other pundits argue that
physicians are reticent to change and
are stuck in their ways. That’s not true
either. Doctors are more likely to
embrace new approaches than any
other profession. The answer must be
looked for within the charting software
itself. Yet, EHR software precisely
replicates the paper charting
How Innovation in
healthcarehealthcare
means going against
entrenched beliefs about the
nature of charting
Expert’s Column
| October 2017 |16

19. methodology used for over a
century. Maybe that’s the problem.
Innovation has not challenged
entrenched beliefs in the old paper
method of charting. The old paper
paradigm remains bound to the past:
an electronic typewriter regurgitating
text inside a dead record.
The problem seems to be not with
the computer but with the original
paper record. Charting on paper
never worked well even before the
first computer ever saw the light of
day in a doctor’s office. Indeed, the
charting paradigm had been
malfunctioning for at least thirty
years, ever since the old three-by-
five cards, used for more than a
Richard Low, Managing Director of
Praxis Electronic Medical Records, is
one of a handful of physician CEOs
running EHR companies. A graduate
from Yale Medical School and
practiced both Emergency Medicine
and Internal Medicine for more than 20
years. Doctor Richard started the
company in 1989 to resolve the main
problem with charting, precious time
being wasted by providers. By learning
from hundreds of medical clients
throughout the years, Praxis is today
more than just an EHR, it is a clinical
tool that enables doctors to provide
better medicine, save time and reduce
professional stress and burnout.
®
Richard Low
Managing Director
17| October 2017 |

20. century to remind clinicians of the patient conditions, were
replaced by reams paperwork as a response to the medical
malpractice litigation beginning in the sixties. Then, with
stacks of medical paper records filed and stacked up to the
ceiling, third-party payers, particularly the government,
began to use this paper as criteria for denial of payment for
services rendered. So what was written on the medical
record became more important than what was done. And
no one questioned the paper approach. As lawyers put it,
“res ipsa loquitor” (the thing speaks for itself), meaning: “if
it’s not written, it it’s not done!”. Sadly, today’s physician
can earn more by spending five minutes with the patient and
twenty minutes with the chart, than by spending twenty
minutes with the patient and five minutes with the chart.
Clearly, there is something profoundly wrong with this
charting approach.
So why did medical software developers maintained the old
charting paradigm in their EHRs instead of giving careful
thought to take advantage of the unique power of the
computer to handle routines better than humans can? The
answer is simple. No one wanted to challenge physicians’
entrenched beliefs that the current way of charting is the
only valid approach. Consequently, programmers worked
on the wrong premise from the start and, by porting it to the
computer, they made it far worse. The argument was
simple: “It had always been done this way.” Except it
wasn’t. Charting the essence of a clinical visit on a three-
by-five-card, as used by our forebears, is not the same as a
computer spitting out tons if complex computer codes to
explain a clinical encounter only because computers cannot
handle human language.
Indeed, after the initial CPT and ICD-9 codes developed by
the AMA and the World Health Organization to describe
acceptable treatments and diagnoses, an array of new codes
appeared on the scene: G-Codes, F-Codes, RxNorm codes,
LOINC Codes, SNOMED codes, the list seems endless.
These codes created havoc for busy practitioners who have
turned into data-entry clerks of a sort, wasting time and
creating stress and confusion, which can lead to clinical
errors. SNOMED in particular is meant to describe the
entire medical exchange: the patient symptoms, the clinical
findings, the diagnoses and all the treatments in
“computerese” rather than English, and drives doctors
completely crazy in the process. Even a new medical
syndrome is being recognized as affecting healthcare
providers called the “Alert Fatigue Syndrome.” Now, the
law of the land is that doctors are to search all these codes
to transmit clinical information to their peers. No one
stopped this insanity and realized that we had the basics
wrong.
So then how should busy clinicians document their clinical
exchanges if not the way they were taught for the last two
hundred years? We, at Praxis Electronic Medical Records,
believe the answer is for the computer to help the providers
think and express themselves using their own thoughts and
words by retrieving them just in time from an artificial
intelligence database so as to learn from their own past
encounters of similar patients. As we like to say: “It’s faster,
easier, and better to do what you wrote than to write what
you did.” Charting backwards? You bet! This is not what
physicians were taught to do, but then again, our forebears
did not have computers to assist them in the examining
room, nor reams of data to fill out, nor attorneys and third
party payers to deal with. They did not need to chart up a
storm to be able practice medicine. The chart then
becomes, not a silly compilation of what is being observed
over and over again, but an actual living checklist that
ensures than nothing is forgotten or overlooked at the point
of care, that all the questions are being asked, all the
relevant findings and studies are being evaluated, and yes, it
also charts instantly so saves about two hours a day.
It seems that doctors had the basics wrong from the start. If
the goal is to practice higher quality medicine by taking
better care of patients, paperwork should not get in the way.
On the contrary, documentation should assist the thought
process, guide it along, and not hinder it. The computer can
do that if it is programmed appropriately.
The concept processing solution works. It has been used for
several years. Praxis EMR is consistently rated number one
in physician user satisfaction studies performed by the
largest medical organizations today, including the American
Academy of Family Physicians the American College of
Physicians, yet few know why Praxis scores so highly.
Indeed, this new charting approach goes against the grain.
It fights against entrenched beliefs about the nature of
documenting medicine. Often for a major change to take
place two things are needed. Technology must represent
disruptive innovation, and there has to be a lot of pain with
the way things had been done up to that point. The latter is
already here among physicians. Doctors today must heal
themselves.
Expert’s Column
| October 2017 |18

22. ecent years have seen exciting discoveries in
RPharma Industries that are generating truly novel
therapeutics for unmet patient needs. In today’s
connected world, the role of the Pharmaceutical Industry is
changing rapidly according to the key trends. Having an
identity in Pharma solutions in place that one can trust
enhances day-to-day living and work life by creating many
more opportunities and encouraging stronger communities.
At the center of this industry, ICM Pharma Pte. Ltd. stands
tall among its contemporaries with providing its unmet
patient needs.
ICM Pharma is amongst Singapore’s largest homegrown
pharmaceutical manufacturers that develops, produces and
markets a wide range of Over The Counter (OTC) and
generic pharmaceuticals, personal care products, and
disinfectants. Being one of the very first manufacturers to
be GMP Certified by the Ministry of Health for the
production of human pharmaceuticals in the 1980s, ICM
Pharma is one of the leading suppliers to public and private
healthcare institutions, clinics and pharmacies in Singapore.
With its wide range of OTC “Minor Ailment Remedies”
found practically in almost every household in Singapore,
ICM Pharma has established itself as a leading and trusted
pharmaceutical manufacturer.
A Leader Who Inspired Change
Founded in 1970 by Koe Khoon Poh, lauded as a pioneer
and Father of Pharmacy in Singapore, ICM Pharma is now
ICM Pharma:
Transforming Science
of Drug Development
Dr. Stuart Koe
Managing Director
helmed by his son, Dr. Stuart Koe, Managing Director of
ICM Pharma. A pharmacist by training, Dr. Stuart, gained
his experience running a dotcom startup for almost 12 years
before joining his father’s company. Since taking over the
management role, he takes all the charge and doubled the
production capacity and improved its operational and
manufacturing excellence with an investment of more than
S$2 million. Also, the company has grown by 30% in an
industry that has been experiencing a climate of stagnation.
ICM Pharma has invested more than €5 million in cutting-
edge biological research that is now in Phase III clinical
trials.
Under the leadership of Dr. Stuart, not only ICM Pharma is
improving its operational and manufacturing excellence.
This shall undoubtedly solidify its business foundation as it
begins to explore overseas regional markets with some of
its award-winning products. Having spent the last few
decades specializing in liquid mixtures, creams and
ointments, today ICM Pharma is also enriching its product
portfolio through the registration of dozens of new generics,
comprising a broad spectrum of medical specialties from
cardiology to oncology.
In an honor to carry forward of his father’s legacy, Dr.
Stuart has also launched a new company, “PharmaKoe”
that entrenches his family name cleverly in the pharmacy
world. With the tagline “Get Better.” PharmaKoe promises
that you will get better in all aspects - health, products,
services. But more importantly, it is a commitment to
improving itself continuously.
| October 2017 |20

23. We know the better
way to fulfill unmet
patient needs; our
best asset is our
people and our
willingness to adapt
or iterate to a
positive outcome
Delivering Solutions and Services with Accuracy
Already armed with its established line of award-winning
products, this strategic expansion of its product offerings
will further augment its competitiveness as it moves into
vast overseas regional markets. In this respect, regional
expansion plans and techno-commercial alliances with
renowned international pharmaceutical players are already
progressing at a rapid pace. The group’s expansive
customer base, both in public and private sectors, can look
forward to a whole new range of products and services
across all the main therapeutic segments.
Bringing Innovation at the “Doors” of Alloksys Life
Sciences
ICM Pharma has invested more than €5 million in cutting-
edge biological research that is now in Phase III clinical
trials across, almost a dozen of reputable hospitals
worldwide. It was the company’s quest for innovation that
culminated in this landmark investment in Alloksys Life
Sciences in 2016, a Dutch biotech company with its
pipeline of novel, life-saving treatments based on the
®
RESCAP platform. The largest investment of its kind by a
Singaporean pharmaceutical company in novel drug
®
development, RESCAP is expected to reach the market in
2019.
Explaining the success: Human capital
ICM Pharma recognizes that its greatest asset is its people.
The company has invested heavily in the human capital to
prepare itself for the next wave of growth. Over the last one
year, it has taken bold steps in creating an executive
leadership team, headed by the CEO, Mr. Nandiraju
Manohar, and pillared with novel and distinct business
verticals. These key positions were filled by attracting the
‘‘ industry’s best talent. ICM Pharma has the rare distinction
of being perhaps the only pharmaceutical company
founded, owned and managed by pharmacists throughout its
long history, which it considers to be one of its competitive
strengths. How this company’s competitive strength has
manifested is the bestowal of multiple prestigious awards
on ICM Pharma, including the Enterprise 50, Singapore
Prestige Brand, SMF Sustainable Growth, Entrepreneur of
the Year, SME 100 – Singapore’s Fast Moving Companies
and the 2017 Dun & Bradstreet Business Eminence Award.
ICM’s role in National Healthcare
As an industry leader and apart from its business and
financial successes, ICM Pharma is playing a key role in its
corporate and social responsibility. Dr. Stuart chairs the Life
Sciences Industry Group (LSIG) at the Singapore
Manufacturing Federation, which functions as the
representative communication platform for the Singapore’s
pharmaceutical industry and the government, regulatory
agencies and foreign countries, in addition to leading the
Singapore Pharmaceutical Manufacturer’s Council and
Singapore Pharmaceutical Trade Organisation. Recognising
the significant macroscopic role it has to play in the national
interests of accessible and low-cost healthcare by
strengthening the capabilities of the local pharmaceutical
industry, ICM is committed to working with these
organizations to serve the country and community by
maintaining world-class quality and safety standards. The
company ensures that the healthcare needs of Singaporeans
will be met with the sustainable availability and supply of
affordable and effective pharmaceutical products and
medicines.
‘‘
21| October 2017 |

24. An Imperative Association between
ei nc cs eo ar nue
d
N
rnae inL g-e
The upsurge of e-learning technologies is evident in education all over the world. Communication and application-
sharing technologies have had a great influence on formal and informal education, particularly through the use of
mobile and wireless devices. E-learning eradicates the barrier of time and distance, forming a universal learning-on-
demand platform.
Understanding the working of brain and how people learn will help e-learning professionals to develop a paramount training
model for business environment. Applying various learning models, as well as what incentives are needed before, during,
and even after the learning process, helps instructional designers deliver a great learning experience for all their students.
While the content, layout and the accessibility of the e-learning course are important, determining how a learner’s brain
actually acquires and retain information is an essential factor of e-learning design and development.
Understanding how the Brain Learns
David Kolb’s famous four-phase model of the learning cycle can be mapped into four major brain processes.
Exclusive
| October 2017 |22

25. Concrete Experience: The information-gathering part of the cycle
engages the sensory cortices through which we hear, see, touch, smell
and taste. They record these concrete experiences in the brain.
Reflective Observation: All of the new data collected from the
sensory cortex flow towards the association regions, where they start
combining to produce a meaningful concept. If we can find meaning
in the subject being learned, the information can move into the
working memory. Although reflection needs time and space to
happen, without these it is impossible for the learners to process,
search for connections, and integrate information. That is why, it
is important to carefully incorporate reflection into the e-learning
materials and significantly improve reflection by inspecting the
amount of information and stride of delivering such information.
It should give students enough time to reflect on the material and
eventually make meaning of it.
Abstract Conceptualization: This brain process occurs
when the prefrontal integrative cortex is completely
engaged. The learner moves past receiving and
absorbing information and is now ready to create
new knowledge, craft relationships and form
abstractions. Thus the learner starts making
meaning in his or her own way and shift from
being a ‘receiver of knowledge’ to a ‘creator of
knowledge’. This is the process that should be
encouraged as it will result in a longer durable
learning.
Active Experimentation: Trying out what you have
learned involves the motor cortex. It is that part of the
brain which converts abstract mental actions into
physical action. After the brain has interpreted
experiences through reflection and built meaning, it uses
these concepts as guides for active experimentation.
Active testing can exhibit in several ways such as reading
another book related to the subject, explaining or discussing
a previous lesson, searching topics online related to a lesson
etc.
Leveraging the Understanding
You cannot argue with the brain. It follows its own rules. For
effective learning, learners need brain-friendly content.
Brain-friendly content is made up of fundamental notions that will
help learners in understanding information deeply and retain it in the long-term
memory. Let’s look at some of the fundamentals an e-learning professional can leverage to develop
and design an effective e-learning model.
No multitasking: For years, multitasking has been considered as an essential skill. However, research has
23| October 2017 |

26. established that our brains do not have the power to multitask. One hemisphere concentrates on one task, while the other is
focused on a completely secondary task. Thus it takes the brain twice as long to complete a task, and also the error rate
goes up by 50%. This is because, we are not ‘multitasking’, we are ‘context switching’. Thus it is important when
designing e-learning courses to avoid modules which ask the user to perform multiple tasks at once, as it hinders the
overall learning process.
Repetition: Do not expect the learners to go through content once and remember it forever. Dedicating attention thrice to a
subject will retain more information. This has a lot to do with associative learning which states that “cells that fire together,
wire together”. Repetition can be tedious, but it need not be. You can review information through knowledge checks as a
form of repetition. Going over same information or ideas, at spaced intervals, can help you create a strong firing pattern in
the brain and thus, allow them to be saved in the long-term memory.
Using Multimedia tools: Multimedia such as images and video, not only engage the learners but also helps them to
actually remember what they have learned. Studies show that students, who use e-books and interactive learning tools, lead
to improved knowledge retention. Furthermore, students who use e-books that contained sound effects, music, audio,
narration, and images were able to retain and recite more information than the ones who read traditional textbooks.
Utilizing such interactive tools also led to group collaboration and interaction thus improving the overall educational
experience.
Gamification: Games help exercise out mental muscles. Not only does it help in engaging learners in the e-learning
process, it also serves as a remedy to boredom that so often leads to unsuccessful learning experiences. According to a
research, students were more motivated to learn mathematics when presented in a gaming format. Even their attitude
towards the subject changed which resulted in an improved overall success and alleviation of boredom that is often
associated with repetition.
Learning is a definite, regular process that occurs inside the brain. There is nothing enigmatic about it. Learning experience
is unique to each learner, so it is important for instructional designers to know how to deliver new information so that
everyone can understand and use it.
| October 2017 |24

28. Over recent years, more companies are incorporating
wellness initiatives into their office environment.
It’s mission critical in todays competitive markets,
to attracting and retain the best talents. One crucial
measurement is the engagement levels of everyone in the
entire organisation. Presenteeism is at an all time high.
People are not motivated by money alone, and wellness
programs are part of the strategy to improve job satisfaction
and productivity. However, only a few companies actually
have comprehensive programs that produce better health
outcomes among employees. As a result, improved
engagement and performance at work, naturally follows
since employees are healthier and happier.
Unfortunately not all health and wellness programs are
successful. The first one or two initiatives may gain traction,
but two years on, and the participation rates decline. One
main problem is that the participants themselves aren’t part
of the creation. Their needs and concerns aren’t addressed
so there’s less motivation for them to commit. So what do
employees want? Here are 5 best practices that help create
successful corporate wellbeing programs that gain true
engagement.
1. Programs Are Doable, Accessible and Sustainable
Imagine a wellness talk or fitness class is starting in 15
minutes. Many employees easily dismiss it and think “I’d
love to go, but I really need to get this work done.” Do
programs run when employees are most busy? Are run after
office hours? And if so, will people stay back for it? Is the
wellness program a broad-based and holistic approach? Or
is it just yoga classes, cooking demonstrations and nothing
else?
Is it easy for participants to learn? What looks easy when a
trained chef prepares a healthy dinner in 20 minutes could
take the average person a lot more time, energy and stress.
Are steps provided for one to implement the new habit,
accomplish their goal and sustain the success?
A comprehensive wellness initiative needs to offer a variety
of scheduled programs that are broken down into
achievable, sustainable habits that create a valuable
outcome. Equally important is that employees can choose
what they are interested in, and easily fit into their schedule.
2. The Work Environment Is Health-Conscious
It’s no use having health and wellness programs if the
physical and psychosocial environment within the office
doesn’t support to healthy habits. Great office design that
support wellbeing has been the trend, since Facebook and
Google showed us how to do it.
Creating creative spaces for smaller pod meetings, having
standing desks and ensuring the cafeteria and vending
machines around the office offer healthier food choices that
can be easily seen are some of the simple ways to
encourage good health. Ensuring regulated noise, inspiring
music, good air quality and temperature and adequate
lighting are also simple yet impactful features of a great
office space.
Allowing ‘down’ times, and work breaks that are
encouraged, is essential. Most people don’t take breaks or
chit-chat because of its negative perception. However this is
absolutely necessary as it create real interaction and real
friendships between co-workers that satisfy the basic human
need for social connections. People need other people to
love, trust and support them, in both business tasks as well
as at a personal level.
3. Wellness Is Integrated Into The Company’s Structure
Further to point 2 above, choosing a healthier lifestyle and
doing well at work shouldn’t feel like a tug-of-war. I’ve
heard of companies who pay for gym memberships for their
staff, which is great. However, when an employee is
working out in the gym, they get a phone call saying they
need to get back in the office because of … (some reason).
Therefore it’s important that a company establishes
wellness programs that are valued and honored in every
aspect of the organization. Otherwise, what’s the point?
Another example includes the holy grail of “work-life
balance”. If your company wants employees to be healthy
and have better
Wellness Program
Top 5 Best Practices
that Defines a Successful
Executive Talk
| October 2017 |26

29. work-life integration, yet at the same time silently imposes
that people must continue working beyond standard office
hours, it really does not make any sense. One (partial)
solution to this is introducing flexi-hours as well as remote
working to allow people to get errands and family
engagements done, as well as work from home, or a cafe
instead of being physically in the office. It’s a partial
solution because giving someone the ability to run errands
and come to work later than usual is great, though it does
not necessarily promote health, happiness or wellbeing.
4. Wellness Is Linked To Continued Support Programs
When a company is genuinely concerned about their
employees’ wellbeing, they will naturally ensure that any
wellness initiative, game or workshop has some form of
continuation. Employee assistance programs (EAP) are
common for mental health concerns, however there needs to
be other support systems in place for other health concerns.
In 2014, Apple’s Cupertino, Calif.-based headquarters
boasted a medical one-stop-shop “wellness center” offering
in-house chiropractic care, dieticians and more. Collective
Works, Singapore, the largest premium co-working space in
Asia, now also houses an in-house chiropractor, specializing
in pain relief, peak performance for both individual and
corporate health.
Gamification of corporate health programs usually run for a
certain period of time. Workshops and classes may run for 8
weeks or throughout the entire year. Although participation
rates are high initially, continued support programs are what
sustains engagement, and creates the change both
individuals and the CEO’s want to see. Engagement is what
creates long term sustainable results.
5. Broad-based Approach
Wellness Programs aren’t all about offering free gym
membership or just having smoking cessation programs.
Health is health – a complete state of physical, mental, and
social well-being. Fitness is “the ability to perform work
(sports, occupations and daily activities) satisfactorily”.
Pilates is a great way to exercise and strengthen the core
muscles, however it is not equivalent to health.
A lot of people know they should quit smoking but doesn’t
because they don’t realize how much damage it can do to
their body. They may not have a strategy, nor enough
motivation to make those changes. One method of offering
voluntary health screenings while giving sound education
and simple tasks from a variety of professionals is the key.
Helping people realise that the company does care, that
their colleagues do care, that they too should care about
their own health is of the greatest importance. Digging
deep, and creating a safe place to improve their lifestyle
choices on multiple levels should be the basis of every
corporate wellbeing initiative.
About the
Author
Dr. Gary Tho, Founder of Chiropractic
Works, a Family Sports and Wellness
clinic in Orchard Road, Singapore. He
specialises in pain relief and preventative
care and believes quality life is essential
for happiness, success and peak
performance. Dr Gary is also the author
of The Pain-Free Desk Warrior, Free
yourself from aches and pains which is
the definitive guide for those stuck at
their desk for more than 2 hours a day.
Dr. Gary Tho
Founder
27| October 2017 |

30. SocialMedia
Marketing
he absence of pharma brands on social media creates a significant void of reputable healthcare information to aid
Tpatients,” writes Dawn Lacallade, LiveWorld’s Chief Social Strategist.
Social media infiltrate virtually every facet of an individual’s digital life. Today, patients are using social media as a major
source of information and healthcare research. Thus, it is essential that pharma companies should be present on social media
to provide full and accurate information to the consumers. To comprehend how social media can assist patients, it is crucial
to understand what compels people to use social media as a source of information.
Social media allows interaction among people which involves exchange and creation of information. It is the perfect conduit
for pharmaceutical companies to connect with their customers, patients and physicians.
According to the current FDA regulations, pharma companies are not able to easily join in a conversation to provide accurate
and balanced information. Regulations dictate that, in a single social post, brands are required to provide precise facts on the
benefits and hazards associated with conditions and products. Due to the character limitations on many social media
platforms, most pharma companies prefer to stay out of the conversation. This results in circulation of falsified information.
This information can be either marginally inaccurate or significantly harmful.
“
for
Market Dashboard
| October 2017 |28

31. Although the communication of pharmaceutical industries is highly
regulated, they are gradually adopting social media platforms to reach and
interact with consumers and healthcare professionals. Here are some of the
top social media practices to look out for:
Crafting Customer Experience
Several marketers think that their job is finished once the sales team
takes over, but in reality, it is just the beginning. The way people
experience your brand will impact the way they think about you, which
will have an enormous effect on the success of your company in the long
run. Devoting a part of the marketing budget to nurture the
existing clientele will make their experience splendid and
thus promote brand loyalty. It is also crucial to respond
whenever your brand in mentioned publicly, whether
positively or negatively, which will help cultivate a
strong and lasting relationship with your customers.
Younger generations are increasingly withdrawing
from traditional social media platforms and adopting
more innovative channels that are more intimate in the
way of communication. To keep up with this challenge,
companies need to find a way to automate the process
wherever possible.
Regulating Content
Pharma companies need to develop content marketing strategies that merge each
piece of content on every channel with their organization’s objectives and
customers’ needs. Creators need to have a clear business objective including the
value that will be delivered to distinct audiences. All companies need to have a
social media compliance officer who will work closely with a corporate legal
counsel and develop a complete strategy and decide if there will be consolidated
social media posting or if individual employees will have the consent to
participate. And lastly, it is critical that all employees understand their role in
corporate social media and be trained on the rules.
Overall Integration
Pharma companies should stop thinking about content marketing and social media
as add-ons. To boost their outcome for clients, content and social marketing need to
be a part of almost every program. To develop a fully integrated program, companies need
to involve influencers and content marketers during the initial stages. Implementing an
organized approach to content and moderation will not only optimize the processes, but also aid
in assuring authorities that all the bases are covered to protect and provide value for the brand.
Investing in Employees
An independent survey discovered that 72% of social media users expect response within an
hour from the brands they follow. This has caused brands to start heavily investing in cross-
functional social media teams that can keep up with the increasing number of client pings
29| October 2017 |

32. every day. Encouraging and incentivizing team members to share brand messages on their own social media accounts, is
predicted to be a game-changer in the coming days. However this cannot be forced, it is essential for employees to want to
share company posts, and along with this the content has to resonate with their own audiences.
Influencer Marketing
Influencer marketing will continue to develop and become an even more established part of the strategy. Currently many
brands try influencer marketing and fail as it is not easy to find effective influencers. Additional data will help in selection
of the right influencers and analyze the results from influencer campaigns. Today, in healthcare, influencers are often
regular people. Some are directly affected by a disease or are being treated with a specific product, while others have
gained a lot of knowledge about a condition and are considered as Subject Matter Experts. The common trend is to select
someone who has an ever-increasing community of followers who value their opinion.
Numerous companies still think of social media as merely a marketing tool which is not true anymore. Consumers learn
about products on different social networks and seek customer service on messaging channels. Moreover, good
storytelling has always been an essential part of effective marketing. But social media is changing the way audiences
consume stories and pharma companies will be required to keep up with the evolution of social storytelling if they want to
remain relevant.
Yet there is still a note of caution with compliance being the foremost priority of pharmaceutical companies. But as
industries are starting to adopt social media without clear regulatory guidance, remaining compliant will be the main
challenge to face.
BUSINESS
MARKETING
| October 2017 |30

34. Mission to deliver the Best in Class Services
Quertle is a leading artificial intelligence (AI) solutions
company dedicated for research and discovery from textual
biomedical information. Biomedical literature is the
backbone of drug discovery and provides a scientific
foundation for the entire healthcare industry. Searching this
vast and constantly growing literature corpus is
fundamental to the work of every pharmaceutical & biotech
company, hospital, and physician and biomedical & life
science research institution. Arising from more than a
decade of research by scientific experts in the field, Quertle
uses machine learning, conceptual understanding, and
predictive visual analytics to transform literature discovery
from a slow, agonizing process to faster development of
new therapies - minimizing costly research mistakes,
making better business decisions and improving physician
awareness.
The Greatest Projects
Central to Quertle’s success was the building of an entirely
new foundation for discovery from textual content – the
BioAI™ platform. Starting with simple natural language
processing and then evolving into a fully fledged AI
approach, capable of learning directly from the text
encountered, the BioAI platform is adaptable and
extensible, supporting unparalleled discovery as well as
integration into pharmaceutical workflows.
Quertle offers its powerful solution via Qinsight™, a
Software as a Service application, which covers biomedical
journal articles, patent grants and applications, treatment
protocols, NIH grant applications, and many other sources
for comprehensive discovery. Soon to be included is the
owadays, most applications used for searching
Nbiomedical literatures are based on keyword
technology, which is more than half a century old
approach. Quertle, a leading AI-based analytics company,
recognized that adding more bells and whistles on top of
that old technology could never suffice. Quertle understood
that artificial intelligence could revolutionize literature
searches and grow as needed in the future. The company
approached this problem from the perspective of
biomedical industry experts, who know a great deal about
data science and programming.
Inspiring Leaders behind Quertle: A Tale of
Researchers
Dr. Jeffrey Saffer and Dr. Vicki Burnett are the Founders
of Quertle. Both are long-time biomedical researchers who
had been personally frustrated by the inefficiencies of
finding critical information in the biomedical literature.
They understood the importance of that literature to R&D
(80% of potential drug targets are identified from the
historical literature), to business decisions such as
Publication Planning and Medical Affairs, and to healthcare
itself. Thus, they were motivated to establish Quertle in
order to re-invent the approaches for using biomedical
literature and transform that process from frustration to
fruitful discovery.
Jeff and Vicki took some time to execute their vision, but it
eventually led to a unique approach that has been validated
by the use of their solutions by pharmaceutical and biotech
companies, universities and research institutions, and
practicing physicians around the world – covering 192
countries.
Quertle:
Transforming AI-Based
Analytics for Biomedical
Big Data
Dr. Jeffrey Saffer
Founder
Dr. Vicki Burnett
Founder
| October 2017 |32

35. Vision is the most important
aspect of starting a business;
if your dreams include
building something of your
own, just do it, and
Quertle is the most Powerful
Biomedical Artificial
Intelligence-based Visual
Analytics Provider that
meets Unmatched Insight
Factiva news from Dow Jones, full-text books and articles
from Oxford University Press and more. Also, Quertle
creates custom applications to incorporate additional visual
analytics, other content sources such as proprietary in-house
documents or healthcare records, and other custom features.
Quertle’s Unique Strategies to Compete in the Global
Market
The key to sales of Quertle’s products is that the
pharmaceutical industry is finally recognizing the
inadequacy of old-fashioned search methods. Hence,
Quertle’s strategy is to make the industry aware of its fully-
functional AI solution that can be put to work immediately.
As a part of this, Quertle makes the following three points.
1. Quertle’s AI methods minimize the risk of missing
critical information: The investments in pharmaceutical
projects are huge. Yet, realizing - after the fact - that
previously known information would have changed project
decisions still remains a commonplace occurrence.
Supplementing current discovery methods with Quertle’s
unique approaches can significantly reduce the money
wasted on these projects.
2. The time required to discover that critical information
is considerably shortened: For example, one user reported
finding out in minutes what previously took an entire team a
full month. This is possible by combining Qinsight’s AI
discovery with the intuitive predictive visual analytics.
3. Quertle’s approach inherently supports serendipity:
Literature searching, by its nature, is geared towards finding
out what you are looking for, and the critical associated
information is often lost. Quertle’s AI automatically
discovers related concepts and presents these in an intuitive
‘‘ exploratory framework, enabling users to have those critical
moments.
Success Attributes towards their Greatest
Accomplishments
Quertle’s success stems from its unique approach, built on
recognition that incremental improvements to outdated
approaches could never solve today’s literature discovery
problems. Gaining worldwide awareness and acceptance of
its methods, and the ensuing impact the technology has had
on pharmaceutical discovery and in saving lives, has been
Quertle’s most significant accomplishment.
Successful Customers, Successful Business
Quertle is growing its customer base through active support
of users. The company understands the industry needs, and
communicates with customers as scientist to scientist. Also,
Quertle provides free training and support with all site
licenses.
Future Aspects
Initially, Quertle’s biggest challenge in the pharmaceutical
industry’s use of textual information was getting individual
users to recognize that the frustrations they feel with
standard approaches are indeed solvable. There is,
fortunately, increasing awareness that AI can help and that
Quertle’s AI, which learns directly from the meaningful text
in the documents, is the future.
The best part of Quertle is imagination – defining a problem
and building a solution, without constraint to prior biases.
This imagination extends through Quertle’s entire team and
is a core value.
‘‘
33| October 2017 |

36. Think about all the inefficiencies in your daily life;
traffic jams, snail mails, long queues, and so on.
These inadequacies though annoying are not a
matter of life and death. Such is not the case in healthcare.
The requirement for efficiency in healthcare is distinct and
the potential for applied sciences especially
computerization is enormous. Healthcare has a big data
opportunity opposed to a big data problem, thanks to
artificial intelligence.
Initially, Artificial Intelligence (AI) was introduced as a
notion to imitate human brain and explore the real-world
problems with a wholesome approach. Researchers all
around the world are thrilled about the upcoming
development of technologies which will help in facilitating
the mankind to deliver outside their stature. The
implementation of AI in healthcare is escalating and
deciphering a variety of issues for patients, hospital and
healthcare industries.
Take a closer look at how AI is resolving problems and
what’s on the horizon for the industry.
Artificial
Intelligence:
A Game Changer
for Healthcare
Innovation Archives
| October 2017 |34

37. Maintaining Health
One of the major advantages of AI is the
ability to assist people in staying healthy.
Mobile applications are already
encouraging instilment of healthy habits in
individuals and assisting in the proactive
management of a healthier lifestyle. It also
increases the ability of healthcare
professionals in understanding the needs of the
people they serve and enables them to provide
a better direction and assistance for maintaining
health.
Furthermore, AI chatbots are being used in addressing
cases like helping customers select a benefit plan,
providing customer service and guiding consumers to
resources. Though it is early in the espousal of AI
chatbots, indicators of requisite and fulfillment are
encouraging. “Chat-bots will continue to get more
intelligent over time, thanks to AI and machine
learning techniques that will make them very
efficient, and of course, more timely than a
human can ever be,” says Khal Rai, an AI
expert at SRS Health.
Early Detection
Cerebrovascular Accident or Stroke,
for a maximum number of times is
caused by blockage in the supply
of oxygen and blood to the
brain. However due to the
lack of detection of early
symptoms, very few
patients are able to
receive timely
treatment. Other
35| October 2017 |

38. conditions like Cancer and Alzheimer’s face similar
consequences. The utilization of AI is enabling review and
analysis of lab reports much faster and with better accuracy.
Recently developed AI software at Houston, Texas claims
to detect cancer risk 30 times faster than any doctor and
with 99 percent accuracy. Moreover, researchers are
training AI to detect Tuberculosis on chest X-Rays which
could help in screening and evaluation in TB-susceptible
zones which lack access to radiologists.
The increase of wearable and other medical devices used in
accordance with AI are also assisting in detecting early-
stage heart diseases and enabling doctors to monitor
potentially life threatening events at an early and treatable
stage.
Medical Diagnosis
Numerous healthcare organizations are applying cognitive
technology to unlock enormous amounts of data and
promote diagnosis. The ability to store more medical
information containing journals, treatments and symptoms
is much faster than any human competency. Earlier,
diagnostic programs regarding disease specific features
were written using predefined assumptions. Now with the
development of AI, a wider variety of conditions and
diseases can be easily handled.
AI is particularly used to improve imaging modalities
which include reading X-Rays, CT scans and doubtful
nodules and lesions in cancer patients. This technology
combines machine learning and neuroscience to generate
powerful learning algorithms into a neural network which
mimics a human brain.
Treatment
Beyond scanning records, AI can
help take a more comprehensive
approach towards disease
management, assist in better
coordination of healthcare
programs and help patients in
managing their long-term
treatment plans. Using AI,
doctors are able to gather
collective information on
patient’s visits and analyze
which treatment works best for
them.
For more than 30 years, robots have been used in medicine.
From simple laboratory robots to highly advanced surgical
robots that can assist a human surgeon or execute it
themselves. Furthermore, they are used in labs and
healthcare organizations for repetitive tasks and in support
of those with long-term conditions.
Customer Service
Healthcare providers are using healthcare bots to tackle
challenges in this area of medicine. Patients can now
interact with AI through phones, or a website for all their
medical queries and requests. Virtual assistants are
replacing humans in booking appointments, scheduling
visits, medication and even billing requirements. They offer
24/7 medical assistance and improve service for any basic
requests. Moreover it leads to the decrease in administrative
costs for healthcare providers.
End-of-Life Care
Life today is much longer than the previous generations,
and we are dying in a different and slower fashion from
conditions like dementia and osteoporosis. It is also a phase
of life which is often lonely. Robots have the potential to
modernize the end of life care and help people in remaining
independent for longer periods of time and reducing the
need for hospitalization and care homes.
Eventually, all of us will be a patient. We have family and
friends who will also be patients. Machine learning and
Artificial Intelligence is about improving the lives of
individuals so that all the acquired data from lab tests,
genomics and so on, can be analyzed and used in real time
for the highest quality and most efficient delivery of
healthcare needs.
| October 2017 |36

40. Danish Hospitals
For more than a decade hospital
productivity has been a priority in
Denmark. A focus on quality and
quality improvements has reduced the rate
of re-admittance to Danish hospitals and a
demand from central authorities on
hospitals to increase their productivity by
2% every year, has during recent years
resulted in a lot of new initiatives and
innovations. With a re-organization of the
Danish hospital structure, this has led to a
total productivity increase of 30% since
2003.
The concept of Hospital Logistics and
Solutions to improve logistics and create
just-in-time scenarios in hospitals is
another factor behind the productivity
increase which is further explained in this
article.
Healthcare systems around the world are
challenged by an increased share of
elderly citizens and chronically ill patients
as well as more expensive forms of
treatment.
These factors are causing a significant
demand pull in terms of treatment needs
as well as expectations, which accentuate
the need for our healthcare systems to
work smarter on all levels. Therefore,
hospitals need to consider means to
increase efficiency and productivity in
order to be able to treat more patients
without increasing costs.
For more than a decade, Danish hospitals
and companies have worked together on
improving logistics in hospitals. The
overall aim has been the creation of
just-in-time solutions in order to optimize
coordination and efficiency and reduce the
patients’ length of stay.
In Denmark, the focus on hospital
logistics has played an important role in
Hospital
Logistics:
Accelerating
the Patient Flow in
| October 2017 |38

41. achieving a 30 pct. increase in hospital productivity since 2003. Optimizing hospital logistics within different areas
of hospital services and needs, including supply logistics, clinical logistics, sterile goods and sample logistics can
accelerate the patient flow and lead to increasing hospital productivity.
‘Just-in-time’ logistics
Innovative hospital logistics solutions are already implemented in Danish hospitals in order to reduce delays and
waiting in order to speed up the patient flow.
Professional’s Particulars
39| October 2017 |

42. Hans Erik Henriksen
Chief Executive Ofcer
Healthcare Denmark
At the New Aarhus University Hospital, a fine-meshed IT system
will enable real-time localization of people and equipment right
down to room level.
At Aalborg University Hospital, the introduction of a similar and
new solution has resulted in a close to 20 pct. efficiency increase.
Danish solutions for just-in-time logistics include systems for
locating and tracking staff and equipment, solutions for
automating basic and repetitive tasks, as well as solutions for
guiding patients around the hospital, all of which help avoid
delays and peak times in the hospital process.
Sample logistics
Accelerating the patient flow is also about reducing the time from
taking a lab test and until the result is ready at the point of care.
At Hospital of Southern Jutland in Aabenraa, the number of
patients has increased by 13 pct., but with the new sample
logistics solution, the hospital has managed to cope and even
reduce the average length of stay.
Intelligent solutions for handling samples help hospitals reduce
their sample turnaround-time and subsequently speed up patient
diagnostics. Fully automated laboratories improve sample flow by
handling and sorting all blood samples without any manual
handling, thereby minimizing the risk of errors and freeing up
time for value-adding tasks such as patient related work.
Sterile goods and sample logistics
The Capital Region in Denmark will centralize all
handling of sterile goods at two departments at Rigs
hospitalet and Herlev Hospital. With fully
automated handling of sterile equipment, the two
centers will improve hygiene and reduce the risk of
infections. At the same time the budget for
purchasing and storing sterile equipment will be
reduced because of the just-in-time solution.
The future
Integrated logistics is the next step. Automatic
delivery of medicine from the hospital pharmacy
directly to the wards and just-in-time
housekeeping, based on the hospital discharge
system, is already a reality in Danish hospitals.
Storage space, which is built directly into the
hospital walls, will prioritize short walking
distances, large coherent clinical areas and patient
related functions.
Denmark is in the process of building 16 new
highly specialized hospitals that are all constructed
as hospitals of the future, taking into account the
changing role of hospitals in our future healthcare
system. While optimal hospital logistics is
important for all existing hospitals, it is vital for the
new, large and specialized hospitals.
| October 2017 |40

44. Revolutionary
Factors Affecting
Pharmaceutical
Industry
Revolutionary
Factors Affecting
Pharmaceutical
Industry
The patient-first business model helps to do just that. The
pharma companies which succeed in patient engagement
increases their chances of commercial and regulatory
success as decisions are taken in accordance with the
patient's needs and results. For productive collaboration
with patients, pharma companies are required to find better
communication techniques and also invest in more effective
data analytics. Although many patients are skeptical about
sharing their personal information, an independent survey
found that most people are willing to let pharma companies
know about their medical activities if it leads to a better
care.
Furthermore, Virtual reality is used to motivate consumers
to be more active and compassionate. If used as a marketing
tool, this can build empathy, enable training on medical
devices and create detailed demos that illustrate the
mechanism of action with extreme clarity and help facilitate
a stronger bond between pharma companies and consumers.
Increase in Biosimilars
Biosimilar products are suspected to continue to have a
significant impact on the pharmaceutical industry. Due to
Editor’s Pick
The world is changing at an ever-increasing pace.
Shopping malls have been replaced with online
shopping; traditional classrooms have given way to
online classes and soon, driving your own car may seem
like a nostalgic activity. Pharmaceutical Industry is no
different. Pharmaceutical and life sciences companies are
facing an upsurge of challenges as a part of what could be
the New Health Economy.
The global pharmaceutical industry is said to have a relative
growth over the next few years. Be on guard for the
following pharmaceutical trends and set the right course for
your strategies.
Patient Empowerment
Gone are the days when individuals relied on doctors for
diagnosis. Due to the easily accessible information, patients
today can learn about their health conditions online and
obtain the necessary knowledge to be aware of the available
treatments and choose the ones they prefer. Doctors have
lost their power to influence this choice and thus pharma
companies have to look for new and innovative ways to get
their medications sold.
| October 2017 |42

45. the increase in approval of biosimilars and their
rapid introduction in the market, market
conditions will have to evolve accordingly. This
will not only provide patients with numerous
treatment options but also have the ability to get
drugs for serious disorders at a much cheaper cost
than the original biologics. This is an opportunity
for manufacturers specializing in generics and
biosimilars to grow their business rapidly. It is
said to be a very sizeable opportunity and if
companies do it correctly, the probability of
success is higher than the traditional
pharmaceutical approach and the cost of
development should be lower than novel drugs.
Precision Medication
Arbitrary costs of trial-and-error therapies and the
increasing need for decreasing the cost of healthcare has
inspired the transition of one-fits-all model to the outcome-
based targeted therapies. Precision medicine eliminates the
need for guesswork, variable diagnosis, and generalized
treatment strategies. Thus far only a few cases exists which
used genetic information to make a decision regarding a
suitable treatment.
Currently, the drug development industry is heavily
investing in precision medicine. Furthermore, scientific
advancements in genomics field suggest that time and costs
are no longer a hindrance for precision medicine. Increasing
awareness about the human genome and its correlation with
disease progression are expected to shift the current focus
beyond oncology.
3D Printed Drugs
3D printing assures a future of drugs being printed on
demand with custom doses and the possibility that price
may no longer be an obstacle. The first 3D printed medicine
that dissolves rapidly is used for the treatment of epilepsy.
02
Small companies are deriving other solutions for creating
drugs that can be metabolized faster and can be marketed
more easily. Because of this entire pharma industry will
have to be restructured within years, perhaps even months.
Digital Healthcare
The global healthcare industry has seen a transformation
which has been driven by advances in biopharmaceutical,
medical and surgical procedures and automation. The
Digital Health applications in information and
communication technologies aid to utilize the full potential
of big data analytics and change the healthcare industry.
Today, if the pharma companies are not thinking about how
to integrate such programs and educational resources and
not just use them as a tool to promote, they will be left
behind.
The digitization of the patient, from the electronic health
records to genome mapping allows for targeted treatment
that is revolutionizing healthcare. The introduction of
mobile health sensors and wearables offers a real-time
insight into a patient’s progress. Furthermore, computers
with the ability to easily analyze enormous amounts of data
and scientific literature can assist pharma companies in the
development of new drugs and improve the existing ones.
Counterfeit Drugs
Counterfeit Drugs are fake medicine. They can be either
contaminated or contain the wrong or lack of active
compound. Pharma companies are required to track the
product ID from manufacturing process and trace its
movement throughout the supply chain. These drugs are not
just available via the black market, but are also accessible
through legitimate pharmacies. Fake drugs are said to be
more deadly than terrorism. An independent survey
concluded that 200,000 people are killed on an average due
to counterfeit drugs.
All of this concludes into the complexity of the supply
chain of pharmaceuticals. With an increased dependence on
outsourced manufacturers and third party logistics, the lack
of clarity across the various components of the supply chain
has never been so blurred. This together with the intrinsic
demand unpredictability from anywhere in the world and
the disparity of supply and demand makes an increasingly
volatile value chain.
43| October 2017 |

47. CUSTOM WEB
DEVELOPMENT
MOBILE
APPLICATION
UI / UX
Custom Web Development
A professionally created website and a remarkable design go
a long way in creating that impression about your business
and thus help in converting a visitor into a customer.
Mobile Application Development
Develop powerful, highly usable apps that solve business
problems, attract users, and reinforce your brand.
UI/ UX
Our role is to offer the expertise and determination to
deliver each site to the utmost standards.
User Engagement
We do it by using artificial intelligence to provide true end to
end personalization and continue to engage shoppers across
unlimited segments to deliver experiences that convert.
USER
ENGAGEMENT
Email id: contact@ascratech.com | Contact No.: +91-9769162289 | www.ascratech.com
WEB AND MOBILE EXPERTS